الفهرس 
Introduction
Clearance of doxorubicinOnly 14 pages are availabe for public view
 |  | from | 183 |  |  |
| | | from | 183 | | |
Abstract
The clinical use of some anthracycline anticancers like doxorubicin is limited by development of progressive cardiomyopathy. Meaning that, cardiotoxicity is an important issue for oncology. Cardiomyopathy induced by chronic chemotherapy with doxorubicin may result, at least in part, from acute cardiotoxic effects accompanying each exposure. Therefore, it is of interest to identify new protective agents that prevent the deleterious cardiac effects during doxorubicin administration. Cardiotoxicity-induced by doxorubicin can be mainly attributed to increased oxidative stress due to production of free radicals and interaction with cellular iron metabolism. On these bases, antioxidants and iron chelators may be used to attenuate this side effect. The present study is an attempt to investigate the cardiotoxicity of doxorubicin as well as prevent it in experimental animals. Cardiotoxicity of doxorubicin was illustrated by mortality in mice, disturbances in normal ECG pattern and effect on aconitine-induced cardiotoxicity in rats as well as assessing some biochemical parameters that reflect cardiac injury in rats such as serum creatine kinase-MB, lactate dehydrogenase and catalase activities as well as myocardial superoxide dismutase activity, malondialdehyde and reduced glutathione contents. The antioxidant, proanthocyanidins and the iron chelator, deferiprone exerted good protection against doxorubicin-induced cardiotoxicity. This protection was evaluated by increasing doxorubicin i.p. LD50 in mice, attenuating the changes in the normal ECG pattern of rats observed following doxorubicin injection and preventing doxorubicin-induced enhancement of aconitine cardiotoxicity in rats. Moreover, they could attenuate the changes in the assessed biochemical parameters associated with doxorubicin-induced oxidative stress and cardiotoxicity. Therefore, both proanthocyanidins and deferiprone may be considered as potentially useful candidates in the combination chemotherapy with doxorubicin to limit its cardiotoxicity. Further clinical studies should be conducted to evaluate the protective effects of proanthocyanidins and deferiprone against doxorubicin-induced cardiotoxicity in cancer patients.